Adenovirus/PNP
- Generic Name
- Adenovirus/PNP
- Drug Type
- Biotech
GeoVax Advances Gedeptin Gene Therapy for Solid Tumors with Expanded Patent Portfolio and Promising Clinical Data
• GeoVax has strengthened its Gedeptin therapy platform with newly allowed patent claims covering the synergistic combination of gene therapy with radiation for treating various solid tumors.
• Clinical data presented at AACR 2025 demonstrated Gedeptin's safety profile and efficacy in heavily pretreated head and neck cancer patients, with median progression-free and overall survival of 7.0 months.
• The company is advancing to a Phase 2 trial combining Gedeptin with pembrolizumab (Keytruda) as a neoadjuvant therapy for relapsed head and neck cancer, leveraging potential synergy with immune checkpoint inhibitors.
GeoVax Advances Multi-Antigen COVID-19 Vaccine and Expands Oncology Pipeline Despite BARDA Setback
• GeoVax's next-generation COVID-19 vaccine GEO-CM04S1 continues clinical development for immunocompromised populations, with key data readouts expected in Q2 2025 despite recent BARDA funding termination.
• The company is advancing Gedeptin® into Phase 2 trials for recurrent head and neck cancer in combination with immune checkpoint inhibitors, having received Orphan Drug designation for this indication.
• GeoVax plans to initiate clinical trials for GEO-MVA, its Mpox/smallpox vaccine candidate, in the second half of 2025, positioning the company to offer a U.S.-developed alternative amid rising global biosecurity threats.
GeoVax Advances Gedeptin and COVID-19 Vaccine Programs Amidst Financial Update
• GeoVax is focusing on advancing its Phase 2 clinical-stage products, Gedeptin for head and neck cancer, and GEO-CM04S1, a next-generation COVID-19 vaccine.
• Gedeptin, a gene-directed enzyme prodrug therapy, targets solid tumors and aims to improve the quality of life for patients with advanced head and neck cancer.
• GEO-CM04S1 differentiates itself by targeting both antibody and cellular immune responses, potentially offering more robust protection for immunocompromised individuals.
• GeoVax is actively seeking partnerships and collaborations for worldwide commercialization and distribution of its products, while also exploring non-dilutive funding opportunities.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath